CPX-351 improves survival following allogeneic hematopoietic cell transplant in acute myeloid leukemia patients

December 5, 2016, H. Lee Moffitt Cancer Center & Research Institute

Acute myeloid leukemia, or AML, is a type of cancer of the blood and bone marrow. It occurs most often in older populations and progresses rapidly, interfering with the production of red blood cells, white blood cells and platelets. Treatments include chemotherapy, drug therapy and stem-cell transplants.

A of a phase 3 trial shows that with high-risk or secondary AML, who received initial treatment with CPX-351, had improved survival following allogeneic hematopoietic cell transplant, when compared with patients who received standard 7+3 cytarabine and daunorubicin as initial therapy. Moffitt Cancer Center physician Jeffrey Lancet, M.D., will present the results at the American Society of Hematology Conference Annual Meeting in San Diego.

Cytarabine combined with daunorubicin (7+3) is commonly used to treat AML; however, older patients with AML usually respond poorly to this treatment regimen alone. Patients who are eligible and respond to initial treatment often have the option to receive allogeneic hematopoietic cell transplants.

CPX-351 is a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio. This fixed molar ratio was found to be synergistic in preclinical studies, and subsequent phase 1 and phase 2 clinical trials demonstrated efficacy, with a particularly strong signal in patients with secondary AML.

Previously reported results from a phase 3 trial revealed improved survival in patients with secondary or high-risk AML treated with CPX-351 compared with 7+3. An exploratory subgroup analysis of the phase 3 study was conducted to compare the outcomes of AML patients treated with CPX-351 or 7+3 who went on to receive allogeneic hematopoietic cell transplant. Out of 309 patients who took part in the trial, 52 patients in the CPX-351 treatment arm and 39 patients in the 7+3 arm received allogeneic hematopoietic cell transplants.

The first 100 days after allogeneic hematopoietic cell transplants represent a critical time. Patients treated with CPX-351 had a lower 100-day mortality rate than patients in the 7+3 group (9.6 percent versus 20.5 percent, respectively). Patients in the CPX-351 group also had a significantly better overall survival than in the 7+3 group. The median overall survival was not yet reached in the CPX-351 arm and was 10.25 months in the 7+3 arm.

Lancet, chair of Moffitt's Department of Malignant Hematology, will present the study results Monday Dec. 5 at 4 p.m. in San Diego Ballroom AB at the Marriott Marquis San Diego Marina.

Explore further: Phase 3 study may be game-changer for acute myeloid leukemia

Related Stories

Phase 3 study may be game-changer for acute myeloid leukemia

April 24, 2014
Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

Study shows age doesn't affect survival outcomes in patients with MDS who receive a HCT

December 6, 2015
Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable ...

Immune cell subset is associated with development of gastrointestinal GVHD after HSCT

May 5, 2016
Gastrointestinal graft vs. host disease (GI-GVHD) is a life threatening complication that can occur after allogeneic hematopoietic cell transplantation, a procedure that is commonly used to treat patients with leukemia. There ...

Study rejects biologic age as limiting factor for stem cell transplants

November 4, 2015
More than 40 percent of older patients with acute myeloid leukemia (AML) can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of ...

Autologous stem cell transplant should be standard care for HIV-associated lymphoma

June 13, 2016
New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment.

HSCT no better than chemo in Philadelphia-negative acute lymphoblastic leukemia

June 3, 2016
(HealthDay)—For patients ≥40 years of age with Philadelphia (Ph)-negative acute lymphoblastic leukemia (ALL), hematopoietic stem-cell transplantation (HSCT) in first remission is associated with lower cumulative incidence ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.